A University of Bristol spin-out firm has raised £415,000 to develop technology which it says could be used to help detect life-threatening diseases at an early stage.
Rosa Biotech said it would use money from its seed funding round to accelerate testing of its platform, called Pandra, which acts as a biosensor on patient blood samples.
The company, founded in 2014 and spun out of the university in 2019, said it was initially targeting the early identification of non-alcoholic fatty liver disease (NAFL) which, the business said, if left untreated can develop into steatohepatitis (NASH), leading to liver failure.
